Trial Profile
A Phase II, 2-stage Trial of CRLX101 in Combination With Bevacizumab in Recurrent Platinum-Resistant Ovarian, Tubal and Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2021
Price :
$35
*
At a glance
- Drugs Camptothecin (Primary) ; Bevacizumab
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Therapeutic Use
- 06 Jul 2021 Results published in the Gynecologic Oncology
- 28 Jun 2018 Status changed from active, no longer recruiting to completed.
- 28 Sep 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.